Peppy vs. Paradigm Peptides: the historical record and today’s care decisions

Disclosure: Peppy Care publishes this comparison of its own service. Public information checked October 22, 2026; no firsthand product testing. Seller statements are attributed, not independently certified.

The Department of Justice case page identifies the business known as Paradigm Peptides or Paradigm R.E. LLC and its historical domain, paradigmpeptides.com. Its purchaser notice covers April 2019 through March 2024. The page records guilty pleas on December 10, 2025 and sentencing on July 30, 2026; it was updated August 3, 2026.

This article uses that dated government record. It does not describe a verified current catalog, compare present prices, or assert that a similarly named website is a continuation of the business. Readers looking for case-specific information should use the government page rather than a competitor’s condensed account.

A legal record identifies particular people, conduct, products, and time periods. Its findings should not be transferred to another seller merely because both use the word “peptide.” Likewise, a historical domain mentioned in the record does not establish who operates any present-day site with a similar name.

The DOJ page includes both investigative descriptions and later court milestones. Those parts should be read with their stated dates and procedural context. This comparison does not relabel every statement on the page as a judicial finding or infer facts about transactions outside its stated scope. Accuracy matters more than using a historical case as a broad marketing claim.

A current healthcare decision needs current professional and product information. Identify the clinician who will assess the patient, the pharmacy that would dispense, the exact medicine, and the evidence for the proposed use. FDA’s online-pharmacy guidance emphasizes prescription requirements, state pharmacy licensing, and pharmacist access.

The absence of a known enforcement record does not prove that a different seller or service meets those standards. Nor does the existence of a historical case prove that every product in a broad category is identical. Our SwissChems comparison discusses another dated regulatory source with its own scope; it is not the same matter as the Paradigm record.

Peppy’s shipping policy describes health-intake review by a licensed provider and prescription transmission to a licensed compounding pharmacy if approved. That process should be confirmed for the reader’s state and circumstances. Ask who provides follow-up, how fees work, and why a particular treatment is recommended.

The FDA’s compounding guidance states that compounded drugs are not FDA-approved. A historical case involving another business cannot establish the safety, effectiveness, or approval of a Peppy preparation. A useful comparison therefore ends with verifiable questions about present care, rather than a claim that one company’s legal history makes another company’s medical offering automatically suitable.